Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins-Reference-Cited by-同舟云学术

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Published:2014-02 Issue:1 Volume:40 Page:93-101
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Remon J.,Morán T.,Majem M.,Reguart N.,Dalmau E.,Márquez-Medina D.,Lianes P.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference114 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

2. LUX-lung 3: a randomized open-label phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations;Yang;J Clin Oncol,2012

3. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways;Sordella;Science,2004

4. Gefitnib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study;Zhou;Lancer Oncol,2011

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis;Frontiers in Oncology;2024-08-13

2. Therapeutic potential of cis-targeting bispecific antibodies;Cell Chemical Biology;2024-08

3. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung;The Kaohsiung Journal of Medical Sciences;2024-03-25

4. Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification;International Cancer Conference Journal;2024-01-02

5. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11